



# Clinical Tools to Assess Asthma Control in Children

Chitra Dinakar, MD, FAAP, Bradley E. Chipps, MD, FAAP, SECTION ON ALLERGY AND IMMUNOLOGY, SECTION ON PEDIATRIC PULMONOLOGY AND SLEEP MEDICINE

Asthma affects an estimated 7 million children and causes significant health care and disease burden. The most recent iteration of the National Heart, Lung and Blood Institute asthma guidelines, the Expert Panel Report 3, emphasizes the assessment and monitoring of asthma control in the management of asthma. Asthma control refers to the degree to which the manifestations of asthma are minimized by therapeutic interventions and the goals of therapy are met. Although assessment of asthma severity is used to guide initiation of therapy, monitoring of asthma control helps determine whether therapy should be maintained or adjusted. The nuances of estimation of asthma control include understanding concepts of current impairment and future risk and incorporating their measurement into clinical practice. Impairment is assessed on the basis of frequency and intensity of symptoms, variations in lung function, and limitations of daily activities. “Risk” refers to the likelihood of exacerbations, progressive loss of lung function, or adverse effects from medications. Currently available ambulatory tools to measure asthma control range from subjective measures, such as patient-reported composite asthma control score instruments or objective measures of lung function, airway hyperreactivity, and biomarkers. Because asthma control exhibits short- and long-term variability, health care providers need to be vigilant regarding the fluctuations in the factors that can create discordance between subjective and objective assessment of asthma control. Familiarity with the properties, application, and relative value of these measures will enable health care providers to choose the optimal set of measures that will adhere to national standards of care and ensure delivery of high-quality care customized to their patients.

## INTRODUCTION

Guidelines from the National Heart, Lung and Blood Institute for the diagnosis and management of asthma, and the Global Initiative for Asthma Control, revolve around the yardstick of evaluation of the severity of asthma and attainment of control to guide initiation and

## abstract

*This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.*

*Clinical reports from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, clinical reports from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.*

*The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.*

*All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.*

**DOI:** 10.1542/peds.2016-3438

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2017 by the American Academy of Pediatrics

**FINANCIAL DISCLOSURE:** The authors have indicated they do not have a financial relationship relevant to this article to disclose.

**FUNDING:** No external funding.

**POTENTIAL CONFLICT OF INTEREST:** The authors have indicated they have no potential conflicts of interest to disclose.

**To cite:** Dinakar C, Chipps BE, AAP SECTION ON ALLERGY AND IMMUNOLOGY, AAP SECTION ON PEDIATRIC PULMONOLOGY AND SLEEP MEDICINE. Clinical Tools to Assess Asthma Control in Children. *Pediatrics*. 2017;139(1):e20163438

adjustment of therapy.<sup>1,2</sup> Numerous studies have confirmed the inadequacy of asthma control in the United States.<sup>3,4</sup>

The domains of severity and control can be assessed in terms of impairment (frequency and intensity of symptoms, variations in lung function, and limitations of daily activities) and future risk (likelihood of exacerbations, progressive loss of lung function, or adverse effects from medications). Asthma can be considered to be well controlled if symptoms are present twice a week or less; rescue bronchodilator medication is used twice a week or less; there is no nocturnal or early awakening; there are no limitations of work, school, or exercise; and the peak flow (PEF)/forced expiratory volume in 1 second (FEV<sub>1</sub>) is normal or at the personal best. Asthma control can be further classified as well controlled, not well controlled, and very poorly controlled as elegantly laid out in the National Heart, Lung and Blood Institute Expert Panel Report 3 (EPR3).<sup>1</sup> Asthma can be considered not well controlled if symptoms are present more than 2 days a week or multiple times on 2 or fewer days per week; rescue bronchodilator medication is used more than 2 days per week; nighttime awakenings are 2 times a month or more; there is some limitation of work, school, or exercise; and the PEF/FEV<sub>1</sub> is 60% to 80% of personal best/predicted, respectively. Asthma is classified as very poorly controlled if symptoms are present throughout the day; rescue bronchodilator medication is used several times per day; nighttime awakenings are more than 1 time a week; there is extreme limitation of work, school, or exercise; and the PEF/FEV<sub>1</sub> is less than 60% of personal best/predicted, respectively.

The keystone of asthma management is the achievement and maintenance of optimal asthma control. However,

to date, there is no universally recognized gold standard measure of asthma control that can accurately capture both patient-reported domains of impairment and risk and objective measures of lung function. The tools available in a clinical practice setting can be classified as subjective (“patient reported”) and objective (“physiologic and inflammatory measures”). A judicious combination of measures from each category may be needed to optimally assess asthma control.

### SUBJECTIVE MEASURES

Subjective measures of asthma control include (1) detailed history taking, (2) use of composite asthma control scores, and (3) quality-of-life measures (used mainly in research settings).

#### History

Assessment of asthma control in the health care provider’s office starts with the history. Detailed information should be sought on patient-centered outcomes (such as asthma exacerbations in the past year and the limitations asthma imposes on the patient’s daily activities including sports and play), sleep disturbance, medication use (both daily controller and reliever medication), adherence to therapy, and comorbidities/factors that may complicate care.<sup>5</sup>

#### Composite Asthma Scores

Patient-reported composite asthma control score instruments are attempts to capture the multidimensional nature of asthma control in a single numerical value. This enables the degree of asthma control to be compared across encounters. More than 17 composite instruments, each with at least 1 published validated study, are available.<sup>6</sup> These instruments have comparable content and have been designed to measure asthma disease activity over a period of 1 to

4 weeks. Notably, none of them have been validated to assess an acute exacerbation (Table 1). Therefore, from a pediatric emergency medicine perspective, caution should be taken when using composite asthma score instruments during an acute exacerbation, as is typically encountered in the emergency department setting.

The commonly used validated tools are the Asthma Control Test (ACT),<sup>7</sup> the Childhood Asthma Control Test C-ACT,<sup>8</sup> and the Asthma Control Questionnaire (ACQ).<sup>9</sup> The ACT contains 5 items, with a recall window of 4 weeks. The C-ACT is for use in children 4 through 11 years of age and consists of 4 pictorial items and 3 verbal items that are scored by the children and parents, respectively. It has been reported that children tend to assess their asthma control to be significantly lower than their parents do. The Asthma Control Questionnaire (ACQ) contains 6 items with a recall window of 1 week, supplemented by percentage of predicted FEV<sub>1</sub> measurement. The Test for Respiratory and Asthma Control in Kids (TRACK)<sup>10</sup> is a 5-question caregiver-completed questionnaire that determines respiratory control in children 0 to 5 years of age with symptoms consistent with asthma. Another less commonly used instrument is the Asthma Therapy Assessment Questionnaire (ATAQ), a 20-item parent-completed questionnaire exploring several domains, with 4 questions relating to symptom control and primarily used in research.<sup>11,12</sup>

Individual instruments contain 3 to 10 questions, and scoring varies by instrument (Table 1). Four instruments have established cutoff values for uncontrolled versus controlled asthma (ACQ, ACT, C-ACT, and TRACK), and 2 have cutoffs for identifying poorly controlled asthma (ACT and ATAQ). Because these cutoffs have been defined

**TABLE 1** Age-Specific Asthma Control Tools and Their Properties

Age	Instrument
0–4 y	TRACK
5–11 y/older children	Asthma Quiz, ATAQ for Children and Adolescents, Breathmobile Assessment of Asthma Control, Asthma Control in Children, Functional Severity of Asthma Scale, C-ACT, and Pediatric Asthma Control Tool
12 y and older	ACT and ACQ
18 y and older	Asthma Control and Communication Instrument, ATAQ, Seattle Asthma Severity and Control Questionnaire, and 30-Second Asthma Test
Comments	Other asthma questionnaires include the Asthma Quiz for Kidz, the 23-item/13-item Pediatric Asthma Quality of Life Questionnaire (PAQLQ)/Mini-PAQLQ, the Pediatric Quality of Life Inventory, the Asthma Routines Questionnaire, and the Pediatric Asthma Control and Communication Instrument
Tool	Properties
ACT (5-item questionnaire)	Composite, numeric score (up to 25) MCID 3 points Controlled >19 Poorly controlled ≤15
C-ACT (7-item questionnaire)	4 filled out by child, 3 questions by parent/caregiver Composite numeric score (up to 27) MCID 2 points Controlled >19
ACQ (7 items: 6 questionnaire, and 1 FEV <sub>1</sub> )	Composite numeric score (up to 6) MCID 0.5 points Controlled >19
ATAQ (4-item questionnaire in the control dimension; overall 20 questions)	Composite numeric score (up to 4)  MCID: none established Controlled (0); not well controlled (1–2), poorly controlled (3–4)
TRACK (5-item questionnaire)	Composite numeric score (up to 100) MCID: 10 Controlled (≥80)

Adapted from Cloutier et al.<sup>6</sup> MCID, minimally clinically important difference.

at a population level, they may not be accurate for an individual patient. Tracking the numerical and categorical responses over time for each individual patient may prove to be more helpful than looking at cutoff values alone. For instance, if a patient reports frequent nocturnal awakenings, following the response to that particular question may help individualize attainment of control. The minimal clinically important differences or temporal differences in scores that indicate clinical significance have been determined for a few of the instruments (ACQ, ACT, C-ACT, and TRACK<sup>6,13</sup>; Table 1). Three of the instruments (ACQ, ACT, and TRACK) have been validated in Spanish-speaking groups.<sup>14–16</sup> The ACQ and ACT have been validated for use as self-administered instruments in person, at home, by telephone, and by Internet tracking.<sup>6,17</sup>

Poor asthma control, as measured by the commonly used composite

scores, is associated with reduced lung function and elevated exhaled nitric oxide fraction<sup>5,18</sup> (discussed later in the article). Studies have shown that changes in these composite scores reflect changes in the overall clinical assessment of asthma control by physicians and the need to step-up therapy.<sup>19</sup> However, a recent study showed that the degree of asthma control, as assessed by these tools, changes over time and shows variable concordance with the risk of exacerbations.<sup>12</sup>

Despite being fairly well validated, these scores share drawbacks that limit their usefulness in clinical practice.<sup>6</sup> Although the short recall window facilitates reliable recollection of recent asthma events, it fails to represent the fluctuations in control. Children may be excellently controlled during one season and then have poor control during another. In addition, asthma exacerbations can occur

in children with good short-term asthma control.<sup>20</sup> Exacerbations, an important component of the impairment domain of asthma control, are not covered in the ACT, C-ACT, and ACQ but are assessed in the TRACK and the Composite Asthma Severity Index.<sup>21,22</sup>

### Quality of Life

A range of pediatric asthma quality-of-life instruments have been developed, encompassing the impact of asthma on children's or their parents' lives.<sup>23</sup> The instruments have been validated but are time-intensive to fill out and are therefore not routinely used in clinical practice.

### OBJECTIVE MEASURES

Currently available objective measures of asthma control include (1) assessment of lung function, (2) evaluation of airway

**TABLE 2** Objective Measures of Asthma Control

Spirometry	<p>Measured by ATS/ERS guidelines and using NHANES-3 normative values. Serial measures should be performed at the same time each day, if possible (Indicate whether bronchodilator was withheld before test.)</p> <p>Standardized methodology and equipment (ATS/ERS guidelines)</p> <p>Performed in a clinic/laboratory setting under the supervision of a qualified technician</p> <p>Can be performed by children &gt;5 y (in general) under guidance of trained personnel</p> <p>Portable and handheld devices available for use in the field/home settings</p> <p>FEV<sub>1</sub> report:</p> <ul style="list-style-type: none"> <li>Percent predicted values (at baseline and at any other time point, if applicable)</li> </ul> <p>Changes over the course of evaluation:</p> <ul style="list-style-type: none"> <li>Percent change from baseline in the absolute value</li> <li>Absolute change from baseline (in milliliters)</li> <li>Change from baseline in the percent predicted value</li> </ul> <p>FEV<sub>1</sub>/FVC report:</p> <ul style="list-style-type: none"> <li>Ratio of absolute values (at baseline and at any other time point, if applicable)</li> </ul> <p>Changes over the course of evaluation:</p> <ul style="list-style-type: none"> <li>Absolute change from baseline in the value of the ratio</li> <li>Change from baseline in the percent predicted value</li> </ul>
Bronchodilator reversibility (prebronchodilator and postbronchodilator spirometry)	<ol style="list-style-type: none"> <li>1. Withhold bronchodilator before the measure (12–24 h for long-acting <math>\beta</math>-2-agonists or anticholinergics; 4–6 h for short-acting <math>\beta</math>-agonists)</li> <li>2. Administer 4 separate puffs of albuterol (90 mg of albuterol base/puff) with spacer at 30-s intervals between puffs, followed by spirometry after 15 min</li> </ol> <p>Report:</p> <ul style="list-style-type: none"> <li>Prebronchodilator and postbronchodilator FEV<sub>1</sub> (expressed as percent predicted)</li> <li>Percent change from prebronchodilator to postbronchodilator in the absolute value of FEV<sub>1</sub></li> <li>Absolute change in FEV<sub>1</sub> from prebronchodilator to postbronchodilator (in milliliters)</li> </ul>
PEF	<p>PEF is a measure of maximum instantaneous expiratory</p> <p>Can be self-administered on a daily basis and results recorded manually or electronically to obtain day-to-day or within-day variability</p> <p>Percent predicted values (NHANES-3 normative values)</p> <p>When measured with a peak flowmeter, PEF is usually expressed in units of L/min; in contrast, when PEF is measured with spirometry systems, it is usually expressed in units of liters/second</p> <p>Percent change from baseline in the absolute values over the course of evaluation</p> <p>Absolute change from baseline over the course of the evaluation (in liters/minute)</p> <p>Variability (diurnal amplitude as a percentage of the day's mean)</p>

Adapted from Tepper et al.<sup>24</sup>

hyperresponsiveness, and (3) biomarkers.

### Assessment of Lung Function

#### Peak Flow

The PEF is defined as the highest instantaneous expiratory flow achieved during a maximal forced expiratory maneuver starting at total lung capacity.<sup>24</sup> PEF variability is the degree to which the PEF varies among multiple measurements performed over time (Table 2). The management of acute exacerbations has traditionally been guided by PEF measurements. However, the correlation between PEF and FEV<sub>1</sub> worsens in asthmatic patients with airflow limitation. Also, although reference to normal PEF values is important, the “personal best” value, and the trend of change in individual

patients, is of greater value in managing their asthma.<sup>24</sup>

The advantages of PEF are that it is easier to perform than a spirometric maneuver and it is measurable with a relatively small and inexpensive instrument. Thus, PEF may be suitable for individual testing at home, at school, and in patients who are poor perceivers of their degree of airway obstruction. It may help prevent delayed treatment in underperceivers and excessive use of services in overperceivers.

Many concerns regarding PEF have been described, with the primary ones being that the results are highly variable even when performed well, limiting its utility in the diagnosis and management of asthma. Parents and child should be appropriately trained

on use, but there is no gauge of effort, and it gives no information regarding the site of airflow obstruction. It cannot distinguish obstructive from restrictive ventilatory impairment. PEF meters from different manufacturers may show different results, and the “personal best” measurements may change with growth and degree of asthma control. Adherence to PEF monitoring is a challenge<sup>25</sup> and is often the reason it is not widely used in clinical practice. Overall, PEF monitoring alone has not been shown to be more effective than symptom monitoring on influencing asthma outcomes<sup>26</sup> and is no longer recommended.<sup>1</sup>

#### Spirometry

Measurement of spirometric indices of lung function, such as the FEV<sub>1</sub>,

forced vital capacity (FVC), and FEV<sub>1</sub>/FVC ratio, are an integral part of the assessment of asthma severity, control, and response to treatment.<sup>1,2</sup> They have been shown to be associated with the risk of asthma attacks in children.<sup>27</sup> Children with chronic airway obstruction have been reported to be less likely to perceive dyspnea than those with acute obstruction.<sup>28</sup> The EPR3, therefore, recommends performing office-based spirometry every 1 to 2 years and more frequently if clinically indicated in children 5 years or older with asthma.<sup>1</sup> However, only 20% to 40% of primary care providers use lung function measurements in asymptomatic asthmatic patients, and up to 59% of pediatricians never perform lung function tests.<sup>29</sup>

Normal values for spirometry are well established and are based on height, age, sex, and race/ethnicity of the healthy US population. Spirometric measures are highly reproducible within testing sessions in approximately 75% of children older than 5 to 6 years of age. Guidance on performing spirometry in an office setting and coding for asthma visits have been described.<sup>30</sup> The forced expiratory maneuver may be displayed as a flow-volume loop. Guidelines regarding interpretation of the primary measures (FEV<sub>1</sub>, FVC, and the FEV<sub>1</sub>/FVC ratio) are well outlined in the EPR3.<sup>1,31</sup> Of note, most automatic interpretations of the spirometry report fail to comment on the FEV<sub>1</sub>/FVC ratio, an important parameter that, in children, is normally 85% predicted or greater.<sup>1</sup> Forced expiratory flow between 25% and 75% of vital capacity (FEF25–75) may reflect obstructive changes that occur in the small airways of children with asthma. However, FEF25–75 is considered to be of secondary importance because it is not specific and is highly variable (effort dependent).

Reduced spirometric measures are associated with symptom severity,

reduced quality of life, and poor asthma outcomes.<sup>24</sup> However, individual patients, particularly children, may have misleadingly normal spirometry results, despite frequent or severe symptoms. An analysis of 2728 children between 4 and 18 years of age attending a tertiary care facility showed that the majority of asthmatic children had FEV<sub>1</sub> values within normal ranges.<sup>32</sup>

Spirometry, by itself, is not useful in establishing the diagnosis of asthma because airflow limitation may be mild or absent, particularly in children. In other words, if the spirometry result is normal, it does not rule out asthma. Variability of airflow obstruction over time and the response to treatment, when clinically relevant, can aid in the diagnosis and assessment of asthma control.

Although there are organizations that are attempting to integrate spirometry results into the electronic health record with varying degrees of success, the most commonly used approach at this time is to scan the printed spirometry result into the electronic health record.

#### *Prebronchodilator and Postbronchodilator Spirometry (Bronchodilator Reversibility)*

Bronchodilator reversibility testing helps determine the presence and magnitude of reversible airflow limitation.<sup>24</sup> Baseline spirometry is performed and repeated after administration of bronchodilator test agents (eg, 15 minutes after 4 inhalations of albuterol). Change in FEV<sub>1</sub> is the most common parameter followed because the value of reversibility in other measurements is less established (eg, FEV<sub>1</sub>/FVC or FEF25–75).

The most widely used definition of “significant” bronchodilator response is that of the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for

interpretation of spirometry and consists of an improvement in FEV<sub>1</sub> greater than 12% and 200 mL.<sup>33</sup> Other parameters that have been used in children include a 9% to 10% increase in percent predicted FEV<sub>1</sub>.<sup>24</sup>

Bronchodilator reversibility testing, although not specific, is useful for confirming the diagnosis of asthma. Increased bronchodilator reversibility correlates with increased asthma severity. Bronchodilator reversibility is diminished in patients with well-controlled asthma as well as those with narrowing or remodeling of the airways. Annual assessment of prebronchodilator and postbronchodilator FEV<sub>1</sub> might help identify children at risk for developing progressive decline in airflow.<sup>34</sup>

#### *Recent Advances in Monitoring PEF and Spirometry*

Advances in home-based airflow monitoring include the use of electronic, handheld devices with easily downloadable recordings of multiple PEF or FEV<sub>1</sub> point measures with software that facilitates easy use and interpretation.<sup>35</sup> The availability of these instruments for routine clinical use is limited at this time.

#### *Impulse Oscillometry*

Impulse oscillometry assesses airflow resistance and bronchodilator response in younger children. Measurement of airway resistance is a direct indicator of airway caliber with increased resistance indicating narrowing of airways. It is used largely as a research tool and is only available in a few centers.<sup>24</sup>

#### **Airway Hyperresponsiveness**

A major characteristic of asthma is the variability in bronchial tone in response to a variety of stimuli. Airway hyperresponsiveness (AHR) may be assessed by bronchial

provocation tests. Bronchial provocation tests may be performed with agents such as methacholine or stimuli such as physical exercise.<sup>24,28,36</sup> A positive test result for AHR is indicated by a 20% reduction in FEV<sub>1</sub> after inhalation of a methacholine dose of 8 mg/mL or less. A negative test suggests a diagnosis other than asthma. A reduction in FEV<sub>1</sub> of at least 10% during exercise testing is taken as a sign of exercise-induced bronchoconstriction. These tests take approximately 2 hours and require trained personnel to perform them. In general, evidence does not support the routine assessment of AHR in the clinical management of asthma control.<sup>28</sup>

### Biomarkers

Apart from exhaled nitric oxide measurements, the role and usefulness of noninvasive biomarkers in routine clinical practice for monitoring inflammation in children with asthma is undefined. Sputum eosinophilia, exhaled breath condensates, and urinary leukotrienes are used as tools primarily in research studies.<sup>28,37</sup>

#### *Exhaled Nitric Oxide*

The fractional concentration of nitric oxide in exhaled air (FENO) is a quantitative measure of airway nitric oxide, an endogenously produced gaseous mediator that is an indirect marker of airway inflammation. The joint ATS/ERS guideline for the measurement of FENO is the current standard.<sup>38,39</sup> The testing is noninvasive, reproducible, easy to perform in patients (including children), feasible to measure in ambulatory clinical settings, and has no risk to patients.<sup>40,41</sup>

FENO is generally accepted as a marker of eosinophilic airway inflammation. Individuals with asthma have been reported to have elevated levels of FENO, but because FENO is also related to atopy,

elevated levels may be seen in atopic individuals without asthma. Although FENO levels overlap among healthy, atopic, and asthmatic cohorts, in general, the upper value of normal is 25 ppb. It has been suggested that a clinically important decrease of FENO is a change of 20% for values greater than 50 ppb or a change of 10 ppb for values less than 50 ppb.<sup>38</sup> Studies in children suggest that FENO correlates with severity and with asthma control.<sup>42</sup> FENO reduces in a dose-dependent manner with corticosteroid treatment<sup>43</sup> and has been shown to increase with deterioration in asthma control.<sup>44</sup> The value of additional FENO monitoring in children whose asthma is appropriately managed using guideline-based strategies is unproven,<sup>28,45-47</sup> and insurance payment for this test varies by geographic location. Nevertheless, some asthma specialists have adopted the use of FENO as an adjunct ambulatory clinical tool for measuring airway inflammation and serial monitoring asthma control in individual patients with difficult-to-control asthma.

#### *Assessing Asthma Control in Children Younger Than 5 Years*

In children younger than 5 years, it is recommended that both symptom control and future risk be monitored.<sup>2</sup> The risk domain is assessed by historical review of exacerbations with need for oral steroid. Validated measures to assess asthma control in this age group include the TRACK (0-5 years) and the C-ACT in children (4-11 years) of age.

Children younger than 5 years are typically unable to perform spirometry; hence, confirmation of the diagnosis of asthma is challenging in this age group. Recurrent wheezing occurs in a large proportion of these children, typically with viral infections. A therapeutic trial of

regular controller therapy (for 1-3 months) may often be necessary to evaluate response and maintenance of control.

Assessment of risk profiles using tools such as the asthma predictive index (API) may be helpful in predicting the likelihood of recurrent wheezing in school-age children. One study showed that children with a positive API had a fourfold to 10-fold greater chance of developing asthma at 6 through 13 years of age than those with a negative API, and 95% of children with a negative API remained free of asthma.<sup>48</sup> The modified API suggests that the diagnosis of asthma in young children with a history of more than 3 episodes of wheezing is more likely if they meet 1 major or 2 minor criteria.<sup>49</sup> Major criteria include a parent with asthma, physician diagnosis of atopic dermatitis, or sensitization to aeroallergens (positive skin or allergen-specific immunoglobulin E test results). Minor criteria include the presence of food allergies or sensitization to milk, egg, and peanut; blood eosinophil counts greater than 4%; or wheezing apart from colds.<sup>49</sup>

### SUMMARY

Recent advances in measuring lung function, biomarker profiles, adherence, utilization and outcomes data, and development of validated questionnaires have made ongoing assessment and monitoring of asthma control a reality. Following is a schema of suggested measures that may be used in routine ambulatory monitoring of asthma control in clinical practice.

#### Initial Consultation

- The encounter between patient and health care provider may involve critical and empathetic listening to the patient and accurate elicitation of symptoms

as indicators for asthma control, aided by validated asthma control tools such as the C-ACT/ACT. A complete environmental and social history should be obtained to evaluate for triggers.<sup>50</sup>

- Airway obstruction and AHR can be assessed by measuring prebronchodilator and postbronchodilator FEV<sub>1</sub>. Some specialists may consider evaluation of airway inflammation by using FENO to be useful.
- Education and training regarding asthma and its management can be provided, taking into consideration the patient's personal preference and goals while creating an individualized action plan.
- Action strategies can be based on either symptoms or objective criteria, such as by monthly monitoring of the age-specific, validated asthma control instrument, or in individualized circumstances, by daily electronic FEV<sub>1</sub> or conventional peak flow monitoring at home.

### Subsequent Visits

- Symptom scores with validated control instruments and FEV<sub>1</sub> can be monitored at subsequent visits along with serial health care utilization data to tailor the medication dose to degree of asthma control. The risk domain is validated by a history of systemic steroid prescription, emergency department visits, or hospitalizations.
- In individuals whose FENO was elevated at the initial visit and shows variation in response to therapy, repeat FENO monitoring may be considered.
- Education regarding asthma triggers, review of inhaler techniques, assessment and reinforcement of adherence, treatment of comorbidities

(eg, gastroesophageal reflux, sinusitis, obesity), and encouragement and fortification of the collaborative provider-patient relationship can be provided at each follow-up visit.

- The need for continued assessment or reassessment by a pediatric allergist or pulmonologist can be considered when faced with challenges in attaining optimal asthma control.
- Information on appropriate coding for the asthma management tools and services provided can be found in the Asthma Coding Fact Sheet at the following link: <https://www.aap.org/asthmacodingfactsheets>.

### LEAD AUTHORS

Chitra Dinakar, MD, FAAP  
Bradley Chipps, MD, PhD, FAAP

### SECTION ON ALLERGY AND IMMUNOLOGY EXECUTIVE COMMITTEE, 2015–2016

Elizabeth C. Matsui, MD, MHS, FAAP, Chair  
Stuart L. Abramson, MD, PhD, AE-C, FAAP  
Chitra Dinakar, MD, FAAP  
Anne-Marie Irani, MD, FAAP  
Jennifer S. Kim, MD, FAAP  
Todd A. Mahr, MD, FAAP, Immediate Past Chair  
Michael Pistiner, MD, FAAP  
Julie Wang, MD, FAAP

### FORMER EXECUTIVE COMMITTEE MEMBERS

Thomas A. Fleisher, MD, FAAP  
Scott H. Sicherer, MD, FAAP  
Paul V. Williams, MD, FAAP

### STAFF

Debra L. Burrowes, MHA

### SECTION ON PEDIATRIC PULMONOLOGY AND SLEEP MEDICINE EXECUTIVE COMMITTEE, 2015–2016

Julie P. Katkin, MD, FAAP, Chair  
Kristin N. Van Hook, MD, FAAP  
Lee J. Brooks, MD, FAAP  
Bonnie B. Hudak, MD, FAAP  
Richard M. Kravitz, MD, FAAP  
Shrutim Paranjape, MD, FAAP  
Michael S. Schechter, MD, FAAP, Immediate Past Chair  
Girish D. Sharma, MD, FAAP  
Dennis C. Stokes, MD, FAAP

### STAFF

Laura Laskosz, MPH

### ABBREVIATIONS

ACT: Asthma Control Test  
ACQ: Asthma Control Questionnaire  
AHR: airway hyperresponsiveness  
ATAQ: Asthma Therapy Assessment Questionnaire  
ATS/ERS: American Thoracic Society/European Respiratory Society  
C-ACT: Childhood Asthma Control  
EPR3: Expert Panel Report 3  
FENO: fractional exhaled nitric oxide  
FEV<sub>1</sub>: forced expiratory volume in 1 second  
FEF25–75: forced expiratory flow between 25% and 75% of vital capacity  
FEV<sub>1</sub>/FVC ratio: ratio of forced expiratory volume in 1 second to forced expiratory volume  
FVC: forced expiratory volume  
PEF: peak flow  
TRACK: Test for Respiratory and Asthma Control in Kids

### REFERENCES

1. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3). Guidelines for the diagnosis and management of asthma—summary report 2007. *J Allergy Clin Immunol*. 2007;120(suppl 5):S94–S138
2. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2015 Update. 2015. Available at: [www.ginasthma.org](http://www.ginasthma.org). Accessed June 14, 2016
3. Fuhlbrigge AL, Adams RJ, Guilbert TW, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines.

*Am J Respir Crit Care Med.*  
2002;166(8):1044–1049

4. Carlton BG, Lucas DO, Ellis EF, Conboy-Ellis K, Shoheiber O, Stempel DA. The status of asthma control and asthma prescribing practices in the United States: results of a large prospective asthma control survey of primary care practices. *J Asthma.* 2005;42(7):529–535
5. Brand PL, Mäkelä MJ, Szeffler SJ, Frischer T, Price D; ERS Task Force Monitoring Asthma in Children. Monitoring asthma in childhood: symptoms, exacerbations and quality of life. *Eur Respir Rev.* 2015;24(136):187–193
6. Cloutier MM, Schatz M, Castro M, et al. Asthma outcomes: composite scores of asthma control. *J Allergy Clin Immunol.* 2012;129(3 Suppl):S24–S33
7. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol.* 2004;113(1):59–65
8. Liu AH, Zeiger RS, Sorkness CA, et al. The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma. *J Allergy Clin Immunol.* 2010;126(2):267–273, 273.e1
9. Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. *Eur Respir J.* 2010;36(6):1410–1416
10. Chipps B, Zeiger RS, Murphy K, et al. Longitudinal validation of the Test for Respiratory and Asthma Control in Kids in pediatric practices. *Pediatrics.* 2011;127(3):e737–e747
11. Skinner EA, Diette GB, Algatt-Bergstrom PJ, et al. The Asthma Therapy Assessment Questionnaire (ATAQ) for children and adolescents. *Dis Manag.* 2004;7(4):305–313
12. Wu AC, Tantisira K, Li L, Schuemann B, Weiss ST, Fuhlbrigge AL; Childhood Asthma Management Program Research Group. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. *Chest.* 2011;140(1):100–107
13. Schatz M, Kosinski M, Yaras AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. *J Allergy Clin Immunol.* 2009;124(4):719–23.e1
14. Okelo SO, Eakin MN, Patino CM, et al. The Pediatric Asthma Control and Communication Instrument asthma questionnaire: for use in diverse children of all ages. *J Allergy Clin Immunol.* 2013;132(1):55–62
15. Picado C, Badiola C, Perulero N, et al; Covalair Investigator Group. Validation of the Spanish version of the Asthma Control Questionnaire. *Clin Ther.* 2008;30(10):1918–1931
16. Rodrigo GJ, Arcos JP, Nannini LJ, et al. Reliability and factor analysis of the Spanish version of the asthma control test. *Ann Allergy Asthma Immunol.* 2008;100(1):17–22
17. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. *J Allergy Clin Immunol.* 2006;117(3):549–556
18. Piacentini GL, Peroni DG, Bodini A, et al. Childhood Asthma Control Test and airway inflammation evaluation in asthmatic children. *Allergy.* 2009;64(12):1753–1757
19. Chipps BE, Zeiger RS, Dorenbaum A, et al; TENOR Study Group. Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort. *Curr Respir Care Rep.* 2012;1(4):259–269
20. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. *J Allergy Clin Immunol.* 2011;128(6):1165–1174
21. Chipps BE, Mellon MM, Murphy KR, Zeiger RS. Test for respiratory and asthma control in kids (TRACK): a validated control tool for preschool-aged children. *J Allergy Clin Immunol.* 2014;133(6):1776
22. Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents. *J Allergy Clin Immunol.* 2012;129(3):694–701
23. Wilson SR, Rand CS, Cabana MD, et al. Asthma outcomes: quality of life. *J Allergy Clin Immunol.* 2012;129(suppl 3):S88–S123
24. Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. *J Allergy Clin Immunol.* 2012;129(suppl 3):S65–S87
25. Kamps AW, Roorda RJ, Brand PL. Peak flow diaries in childhood asthma are unreliable. *Thorax.* 2001;56(3):180–182
26. Gibson PG. Monitoring the patient with asthma: an evidence-based approach. *J Allergy Clin Immunol.* 2000;106(1 pt 1):17–26
27. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. *J Allergy Clin Immunol.* 2001;107(1):61–67
28. Moeller A, Carlsen KH, Sly PD, et al; ERS Task Force Monitoring Asthma in Children. Monitoring asthma in childhood: lung function, bronchial responsiveness and inflammation. *Eur Respir Rev.* 2015;24(136):204–215
29. Dombkowski KJ, Hassan F, Wasilevich EA, Clark SJ. Spirometry use among pediatric primary care physicians. *Pediatrics.* 2010;126(4):682–687
30. American Academy of Pediatrics. Coding fact sheets and billing position papers. Available at: [www.aap.org/asthmacodingfactsheets](http://www.aap.org/asthmacodingfactsheets). Accessed December 23, 2015
31. Spahn JD, Chipps BE. Office-based objective measures in childhood asthma. *J Pediatr.* 2006;148(1):11–15
32. Paull K, Covar R, Jain N, Gelfand EW, Spahn JD. Do NHLBI lung function criteria apply to children? A cross-sectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999–2002. *Pediatr Pulmonol.* 2005;39(4):311–317
33. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. *Eur Respir J.* 2005;26(2):319–338
34. Horak E, Lanigan A, Roberts M, et al. Longitudinal study of childhood wheezy bronchitis and asthma: outcome at age 42. *BMJ.* 2003;326(7386):422–423



35. Vilozni D, Barak A, Efrati O, et al. The role of computer games in measuring spirometry in healthy and “asthmatic” preschool children. *Chest*. 2005;128(3):1146–1155
36. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med*. 2000;161(1):309–329
37. Szeffler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. *J Allergy Clin Immunol*. 2012;129(suppl 3):S9–S23
38. Dweik RA, Boggs PB, Erzurum SC, et al; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med*. 2011;184(5):602–615
39. AAAAI/ACAAI Joint Statement of Support of the ATS Clinical Practice Guideline. Interpretation of Exhaled Nitric Oxide for Clinical Applications. Available at: [www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/My%20Membership/FeNOJointStatement3-6-12.pdf](http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/My%20Membership/FeNOJointStatement3-6-12.pdf). Accessed June 14, 2016
40. Dinakar C. Exhaled nitric oxide in asthma management. *Ann Allergy Asthma Immunol*. 2012;108(4):219–222
41. Hanson JR, De Lurgio SA, Williams DD, Dinakar C. Office-based exhaled nitric oxide measurement in children 4 years of age and older. *Ann Allergy Asthma Immunol*. 2013;111(5):358–363
42. Delgado-Corcoran C, Kisson N, Murphy SP, Duckworth LJ. Exhaled nitric oxide reflects asthma severity and asthma control. *Pediatr Crit Care Med*. 2004;5(1):48–52
43. Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Barnes PJ. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. *Thorax*. 2002;57(10):889–896
44. Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. *Am J Respir Crit Care Med*. 2001;164(5):738–743
45. Szeffler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. *Lancet*. 2008;372(9643):1065–1072
46. Patsky HL, Cates CJ, Li A, Kynaston JA, Turner C, Chang AB. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. *Cochrane Syst Database Rev*. 2009(4):CD006340
47. Patsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). *Thorax*. 2012;67(3):199–208
48. Castro-Rodríguez JA, Holberg GJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med*. 2000;162(4 pt 1):1403–1406
49. Chang TS, Lemanske RF Jr, Guilbert TW, et al. Evaluation of the modified asthma predictive index in high-risk preschool children. *J Allergy Clin Immunol Pract*. 2013;1(2):152–156
50. Matsui E, Abramson S, Sandel M; American Academy of Pediatrics, Section on Allergy and Immunology. Clinical report: indoor environmental control practices and asthma management. *Pediatrics*. Available at <http://pediatrics.aappublications.org/content/early/2016/10/27/peds.2016-2589>. Accessed November 8, 2016

**Clinical Tools to Assess Asthma Control in Children**  
Chitra Dinakar, Bradley E. Chipps, SECTION ON ALLERGY AND  
IMMUNOLOGY and SECTION ON PEDIATRIC PULMONOLOGY AND SLEEP  
MEDICINE

*Pediatrics* 2017;139;

DOI: 10.1542/peds.2016-3438 originally published online December 26, 2016;

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://pediatrics.aappublications.org/content/139/1/e20163438">http://pediatrics.aappublications.org/content/139/1/e20163438</a>
<b>References</b>	This article cites 46 articles, 10 of which you can access for free at: <a href="http://pediatrics.aappublications.org/content/139/1/e20163438.full#ref-list-1">http://pediatrics.aappublications.org/content/139/1/e20163438.full#ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Section on Allergy and Immunology</b> <a href="http://classic.pediatrics.aappublications.org/cgi/collection/section_on_allergy_and_immunology">http://classic.pediatrics.aappublications.org/cgi/collection/section_on_allergy_and_immunology</a> <b>Section on Pediatric Pulmonology and Sleep Medicine</b> <a href="http://classic.pediatrics.aappublications.org/cgi/collection/section-on-pediatric-pulmonology-and-sleep-medicine">http://classic.pediatrics.aappublications.org/cgi/collection/section-on-pediatric-pulmonology-and-sleep-medicine</a> <b>Allergy/Immunology</b> <a href="http://classic.pediatrics.aappublications.org/cgi/collection/allergy:immunology_sub">http://classic.pediatrics.aappublications.org/cgi/collection/allergy:immunology_sub</a> <b>Asthma</b> <a href="http://classic.pediatrics.aappublications.org/cgi/collection/asthma_sub">http://classic.pediatrics.aappublications.org/cgi/collection/asthma_sub</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="https://shop.aap.org/licensing-permissions/">https://shop.aap.org/licensing-permissions/</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://classic.pediatrics.aappublications.org/content/reprints">http://classic.pediatrics.aappublications.org/content/reprints</a>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2017 by the American Academy of Pediatrics. All rights reserved. Print ISSN:

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Clinical Tools to Assess Asthma Control in Children**

Chitra Dinakar, Bradley E. Chipps, SECTION ON ALLERGY AND IMMUNOLOGY and SECTION ON PEDIATRIC PULMONOLOGY AND SLEEP MEDICINE

*Pediatrics* 2017;139;

DOI: 10.1542/peds.2016-3438 originally published online December 26, 2016;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/139/1/e20163438>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2017 by the American Academy of Pediatrics. All rights reserved. Print ISSN:

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

